Oral Presentation
ALL-ORAL DECITABINE-CEDAZURIDINE (DEC-C) + VENETOCLAX (VEN) IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) INELIGIBLE FOR INDUCTION CHEMOTHERAPY: PHASE 1/2 CLINICAL TRIAL RESULTS
Roboz G, Zeidan A, Mannis G, et al.
By downloading this material, you acknowledge that this action may be considered a transfer of value and will be reported by Taiho Oncology, Inc. in accordance with applicable Transparency and Sunshine Act requirements.